A new option for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) has been introduced in Korea with the approval of Voydeya (danicopan), a first-in-class oral factor D inhibitor.

Voydeya is AstraZeneca Korea's PNH treatment that was approved by the Ministry of Food and Drug Safety (MFDS) on March 28th.

Voydeya is a first-in-class oral factor D inhibitor and can be used as an add-on therapy to ravulizumab (Ultomiris) or eculizumab (Soliris) for PNH patients with symptoms or signs of extravascular haemolysis (EVH) i in patients who are already receiving a C5 inhibitor (ravulizumab or eculizumab).

PNH is a rare disease caused by acquired genetic mutation that resu